Replies to post #202682 on Avid Bioservices Inc (CDMO)

[Protector]

Frustrated, you know very well that those trials have been done over because the NIH wanted PPHM to use the new dual catheter. Again, you bring up stuff that is behind PPHM's doing. The SEC and the NIH can request such things whether PPH likes it or doesn't. If that is what we must hold against them I think they go free, AGAIN.

Now JUST IN CASE you meant 2013 and the PIII approval. Yes, Cotara in Brain is a NICHE market (hence the orphan drug in US and EU granted and Fast Track because there is a need).

But THEY DID IT! The got the PIII approved and said they will NOT invest in it because Bavituximab is the FOCUS and hence try to find a partner. And in a NICHE that takes time because the partner must evaluate PPHM Cost = PIII cost versus market and ROI. And since Cotara works for all solid tumours you'll have legal discussions to what extend a partner (or buy-out) would be able to use Cotara and in what countries.

Takes time. Just comparing it to any other regular, more mainstream, drug negotiations is to simple.

[until2000]

Certainly companies should be held accountable for what they say. But, I have come to believe that Peregrine has no intention of taking a partner. And if so, any partnership would only be on terms dictated by them. It may be another reason for wall street's hesitation to sign on. Bad behavior among their peers. Just my opinion of course.